drugset / Trial / NCT01243385

Metformin Hydrochloride as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Prostate Cancer

NCT01243385 ↗

Phase 2 Completed 44 enrolled Swiss Cancer Institute
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Metformin hydrochloride may make some enzymes active. These enzymes may block other enzymes needed for cell growth and stop the growth of tumor cells. PURPOSE: This phase II trial is studying the safety of giving metformin hydrochloride as first-line therapy in treating patients with locally advanced or metastatic prostate cancer.

Timeline

Start
2010-12-23
Primary completion
2012-04-17
Completion
2019-08-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Metformin Small molecule 1000 mg Oral

Indications